vaccine Archives | Page 5 of 8 | Be Korea-savvy
Novavax to Participate in H.C. Wainwright Fireside Chat Series

Novavax to Participate in H.C. Wainwright Fireside Chat Series

GAITHERSBURG, Md., June 24 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic [...]

S. Korea to Conduct Tests of COVID-19 Vaccine, Treatment Candidates on Monkeys This Month

S. Korea to Conduct Tests of COVID-19 Vaccine, Treatment Candidates on Monkeys This Month

SEOUL, June 17 (Korea Bizwire) — South Korea will test treatment and vaccine candidates against the new coronavirus on monkeys this month, the science ministry said Wednesday. Two experimental treatments and one vaccine candidate against the novel coronavirus under development by unidentified firms or research organizations will be tested on monkeys as part of the [...]

Sabin Vaccine Institute’s Boost Community Prepares Immunization Professionals to Lead During the COVID-19 Crisis

Sabin Vaccine Institute’s Boost Community Prepares Immunization Professionals to Lead During the COVID-19 Crisis

WASHINGTON, June 16 (Korea Bizwire) — Amid the evolving global challenges posed by the novel coronavirus pandemic, immunization professionals must now grapple with deploying routine immunization services in a daunting and ever-shifting landscape. In a recent survey of 800 immunization professionals conducted by the World Health Organization (WHO), the Sabin Vaccine Institute (Sabin) and other [...]

Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital

Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital

GAITHERSBURG, Md., June 8 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at [...]

Remdesivir Shortens COVID-19 Recovery Time, but Limits Exist

Remdesivir Shortens COVID-19 Recovery Time, but Limits Exist

SEOUL, June 8 (Korea Bizwire) — Remdesivir shortens recovery time for novel coronavirus patients, but the experimental drug conventionally used for treating Ebola has limited efficacy in severe cases, health experts said Monday. Last week, the Ministry of Food and Drug Safety, South Korea’s drug safety watchdog, approved the use of Remdesivir as a treatment [...]

Novavax Awarded Department of Defense Contract for COVID-19 Vaccine

Novavax Awarded Department of Defense Contract for COVID-19 Vaccine

GAITHERSBURG, Md., June 4 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein [...]

Novavax Expands Large-Scale Global Manufacturing Capacity

Novavax Expands Large-Scale Global Manufacturing Capacity

GAITHERSBURG, Md., May 27 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million. The acquisition includes a biologics manufacturing facility and associated assets [...]

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

GAITHERSBURG, Md., May 25 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVX‑CoV2373 includes Novavax’ proprietary [...]